Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
COMMENTARY
Japan Moves to Break Plasma Product Capacity Crunch with Factory Aid
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for new manufacturing capacity, seeking to reverse a sharp decline in the country’s self-sufficiency in immunoglobulin products. The Ministry of Health,…
To read the full story
Related Article
- JB Banks on Sustained Aid to Double Plasma Processing Capacity
October 27, 2026
- KM Biologics Eyes Plasma Product Capacity Expansion with Govt Backing
September 30, 2026
- MHLW Pharma Bureau Eyes 12 Billion Yen to Boost Plasma Product Production
August 28, 2026
- Japan to Consider Support for Domestic Immunoglobulin Production: Minister
July 16, 2026
- JB to Build New Plant in Hokkaido to Double Ig Production
July 8, 2026
- Japan’s Immunoglobulin Self-Sufficiency Rate Falls Below 60%
June 29, 2026
- Takeda to Reevaluate Osaka Plasma Facility Plan as Costs Mount
October 1, 2025
COMMENTARY
- Alzheimer’s Pipeline Looks Past Amyloid to Earlier Intervention, Tau Targets
October 28, 2026
- Lp(a) Drugs Face Next Test in Quest to Cut Cardiovascular Risk
October 19, 2026
- Japan Moves to Break Plasma Product Capacity Crunch with Factory Aid
October 6, 2026
- Survodutide Could Carve Out Role in MASH as Next-Gen Dual Agonist
September 28, 2026
- Regional Formularies Gain Ground, Raising Stakes for Drug Makers, Wholesalers
September 15, 2026
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…